These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1575 related items for PubMed ID: 17077948

  • 1. Acromegaly.
    Scacchi M, Cavagnini F.
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [Abstract] [Full Text] [Related]

  • 2. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
    Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A.
    Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
    [Abstract] [Full Text] [Related]

  • 3. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T, Rutkowski MJ, Micko A, Shiroishi M, Jason Liu CS, Wrobel B, Carmichael J, Zada G.
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [Abstract] [Full Text] [Related]

  • 4. Pituitary tumours: acromegaly.
    Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J.
    Best Pract Res Clin Endocrinol Metab; 2009 Oct; 23(5):555-74. PubMed ID: 19945023
    [Abstract] [Full Text] [Related]

  • 5. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
    Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
    [Abstract] [Full Text] [Related]

  • 6. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
    Gheorghiu ML, Găloiu S, Vintilă M, Purice M, Hortopan D, Dumitraşcu A, Coculescu M, Poiană C.
    Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
    [Abstract] [Full Text] [Related]

  • 7. [Advances in the treatment of acromegaly].
    Krysiak R, Okopień B, Marek B.
    Pol Merkur Lekarski; 2008 Jan; 24(139):59-65. PubMed ID: 18634256
    [Abstract] [Full Text] [Related]

  • 8. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A, Tóth M, Patócs A, Szücs N, Igaz P, Pusztai P, Czirják S, Beko G, Gláz E, Rácz K, Tulassay Z.
    Orv Hetil; 2009 Aug 02; 150(31):1457-62. PubMed ID: 19617182
    [Abstract] [Full Text] [Related]

  • 9. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy.
    Attanasio R, Montini M, Valota M, Cortesi L, Barbò R, Biroli F, Tonnarelli G, Albizzi M, Testa RM, Pagani G.
    Pituitary; 2008 Aug 02; 11(1):1-11. PubMed ID: 17690987
    [Abstract] [Full Text] [Related]

  • 10. The efficacy of medical treatment in patients with acromegaly in clinical practice.
    Lee SY, Kim JH, Lee JH, Kim YH, Cha HJ, Kim SW, Paek SH, Shin CS.
    Endocr J; 2018 Jan 30; 65(1):33-41. PubMed ID: 28931779
    [Abstract] [Full Text] [Related]

  • 11. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A.
    Neuroendocrinology; 2006 Jan 30; 83(3-4):249-57. PubMed ID: 17047390
    [Abstract] [Full Text] [Related]

  • 12. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA, Almeida JP, de Albuquerque LA, Gomes E, Schops M, Ferraz T.
    Neurosurg Focus; 2010 Oct 30; 29(4):E7. PubMed ID: 20887132
    [Abstract] [Full Text] [Related]

  • 13. Acromegaly.
    Chanson P, Salenave S, Kamenicky P.
    Handb Clin Neurol; 2014 Oct 30; 124():197-219. PubMed ID: 25248589
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of pituitary adenomas].
    Mezosi E, Nemes O.
    Orv Hetil; 2009 Sep 27; 150(39):1803-10. PubMed ID: 19758960
    [Abstract] [Full Text] [Related]

  • 15. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
    Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ.
    Drugs; 2009 Nov 12; 69(16):2207-26. PubMed ID: 19852525
    [Abstract] [Full Text] [Related]

  • 16. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar 12; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 17. [Current diagnosis and treatment of acromegaly].
    Melgar V, Espinosa E, Cuenca D, Valle V, Mercado M.
    Rev Med Inst Mex Seguro Soc; 2015 Mar 12; 53(1):74-83. PubMed ID: 25680646
    [Abstract] [Full Text] [Related]

  • 18. Management of endocrine disease: GH excess: diagnosis and medical therapy.
    Andersen M.
    Eur J Endocrinol; 2014 Jan 12; 170(1):R31-41. PubMed ID: 24144967
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec 12; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 20. Cost of management of invasive growth hormone-secreting macroadenoma.
    Luque-Ramírez M, Paramo C, Varela da Costa C, García-Mayor RV.
    J Endocrinol Invest; 2007 Dec 12; 30(7):541-5. PubMed ID: 17848835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.